ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

1. Presentation number: 397P / Poster: ID 680

Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients

Presenter: Ching-Liang Ho MD, et.al. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan.

Session Title: E-poster Display session – Thoracic tumours, metastatic

Session Date and Time: Friday, November 20, 2020. 9:00 – 20:00 Eastern Time

https://cslide.ctimeetingtech.com/asia2020/attendee/confcal/show/session/87#presentati on-abstract-6801974474295

2. Presentation number: 71MO / Oral: ID 798

Title: OBI-833 was safe and immunogenic, without treatment-related SAEs, in a Phase 1 dose-escalation trial

Presenter: Her-Shyong Shiah, MD*., et.al. Department of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan

*current affiliation: Department of Hematology and Oncology, Taipei Tzu Chi Hospital, Taipei, Taiwan

Session Title: Mini-oral session – Developmental and Precision Medicine

Session Date and Time: Friday, November 20, 2020. 19:52 – 19:57 Eastern Time

https://cslide.ctimeetingtech.com/asia2020/attendee/confcal/show/session/64#presentati on-abstract-798375249763